Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

OBJECTIVES: To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or vice versa, in patients with rheumatoid arthritis with non-response or incomplete-response to the initial therapy. METHODS: SELECT-COMPARE randomised patients to upadacitinib 15 mg once daily (n=651),...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy M, Blanco, Ricardo, Hall, Stephen, Thomson, Glen T D, Van den Bosch, Filip E, Zerbini, Cristiano, Bessette, Louis, Enejosa, Jeffrey, Li, Yihan, Song, Yanna, DeMasi, Ryan, Song, In-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958110/
https://www.ncbi.nlm.nih.gov/pubmed/33148701
http://dx.doi.org/10.1136/annrheumdis-2020-218412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958110/
https://www.ncbi.nlm.nih.gov/pubmed/33148701
http://dx.doi.org/10.1136/annrheumdis-2020-218412

Ejemplares similares